热门资讯> 正文
FibroBiologics GAAP每股收益为-0.27美元
2024-05-16 03:24
- FibroBiologics press release (NASDAQ:FBLG): Q1 GAAP EPS of -$0.27.
- Cash and cash equivalents consist of unrestricted cash balances and short-term, liquid investments with an original maturity date of three months or less at the time of purchase.
- The Company had $6,039 thousand and no cash equivalents as of March 31, 2024 and December 31, 2023, respectively.
More on FibroBiologics
- FibroBiologics reports encouraging early data for diabetes cell therapy
- Financial information for FibroBiologics
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。